No Data
No Data
Tong Ren Tang Sinopharm (03613): Chen Fei appointed as acting CEO
Tong Ren Tang Sinopharm (03613) announced that Yu Jin has resigned as the company's executive director and CEO due to personal matters...
Damo: Maintaining Tong Ren Tang Sinopharm's (03613) “Gain” Rating and Lowering the Target Price to HK$15
According to the optimistic hypothesis, Tongrentang Sinopharm (03613) sales growth is 20% or more per year.
Tong Ren Tang Sinopharm Announces 2023 Annual Results Profit attributable to shareholders of HK$540 million, a decrease of 16.3% year-on-year
Tong Ren Tang Sinopharm (03613) announced its results for the year ended December 31, 2023. The group achieved revenue of HK$1,525 million, a year-on-year decrease of 11.9%; profit attributable to company owners of HK$540 million, a year-on-year decrease of 16.3%; basic profit per share of HK$0.65; and proposed to pay a final dividend of HK$0.33 per common share.
Tong Ren Tang Sinopharm will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of HK$0.33 per share on June 17, 2024.
Tong Ren Tang Sinopharm (03613) will pay a final dividend of HK$0.33 per share on June 17
Tong Ren Tang Sinopharm (03613) announced that the company will pay a final dividend of 0 per share on June 17, 2024...
Tong Ren Tang Sinopharm (03613) announced 2023 annual results. Profit attributable to shareholders of HK$540 million decreased by 16.3% year-on-year
Tongrentang Sinopharm (03613) announced its annual results for the year ended December 31, 2023, and the group achieved acceptance during the period...
No Data